Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 3, 2025, Standard BioTools Inc. (the "Company") and Jeremy Davis, the Company's Chief Commercial Officer, mutually determined that Mr. Davis will no longer serve in such position, effective as of February 1, 2025. The Company expects to enter into a severance agreement with Mr. Davis (the "Severance Agreement"), the terms of which the Company expects to be consistent with the Company's 2024 Change of Control and Severance Plan and the Participation Agreement thereunder with Mr. Davis, and Mr. Davis will also be entitled to receive his bonus for the 2024 fiscal year. The Severance Agreement will provide, among other things, that (i) the Company will pay severance to Mr. Davis as a continuation of payments in an amount equal to Mr. Davis' current annual base salary for a twelve-month period, which will total $441,000, (ii) Mr. Davis will be entitled to receive his bonus for the 2024 fiscal year in the amount of $169,785, (iii) the Company will pay Mr. Davis a pro-rated lump-sum payment of his current annual target bonus equal to $21,264.65, (iv) the Company will pay the costs of COBRA premiums for Mr. Davis, his spouse, and his other dependents for the earlier of February 28, 2026 or until his right to such COBRA continuation coverage ends, and (v) Mr. Davis will receive 100% vesting acceleration of his outstanding and unvested equity awards, provided that, if an equity award is to vest and/or the amount of the award to vest is to be determined based on the achievement of performance criteria, then, unless expressly otherwise provided in the applicable equity award agreement, 100% of such equity award will vest assuming the applicable performance criteria had been achieved at target levels for the relevant performance period(s). The Severance Agreement will also include a release and waiver by Mr. Davis and other customary provisions.

The foregoing description of the Severance Agreement is not complete and is qualified in its entirety by reference to the full text of the Severance Agreement, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.